« Return to News | Drug Sponsors

Biocon and Pfizer conclude commercialization agreement

Thursday, March 15, 2012 06:01 AM

India-based biotech Biocon and Pfizer have concluded their alliance to commercialize Biocon's biosimilar versions of insulin and insulin analog products.

The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interests to move forward independently. As of March 12, 2012, all rights licensed to Pfizer reverted to Biocon, and all insulin distributed under the brand name Univia and Glarvia were commercially available, exclusively manufactured, supplied, marketed and supported by Biocon.

"Biocon remains committed to delivering its biosimilar insulin portfolio to global markets in its endeavor to make a difference to diabetic patients across emerging and developed economies,” said Kiran Mazumdar Shaw, chairman and managing director, Biocon. “Biocon will continue to work with its existing partners in several markets and will pursue a commercial strategy on its own and through new alliances in other markets."

"In addition, [Pfizer] will continue to be active in our own research and business development efforts for diabetes, which represents a huge unmet medical need, and we remain committed to seeking new solutions to help physicians and patients,” said Diem Nguyen, general manager of biosimilars, Pfizer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.